Cargando…
The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies
Epilepsy is one of the most common neurological chronic disorders, with an estimated prevalence of 0. 5 – 1%. Currently, treatment options for epilepsy are predominantly based on the administration of symptomatic therapy. Most patients are able to achieve seizure freedom by the first two appropriate...
Autores principales: | Fattorusso, Antonella, Matricardi, Sara, Mencaroni, Elisabetta, Dell'Isola, Giovanni Battista, Di Cara, Giuseppe, Striano, Pasquale, Verrotti, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258148/ https://www.ncbi.nlm.nih.gov/pubmed/34239494 http://dx.doi.org/10.3389/fneur.2021.674483 |
Ejemplares similares
-
Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine
por: Dini, Gianluca, et al.
Publicado: (2022) -
Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine
por: Dini, Gianluca, et al.
Publicado: (2023) -
The Broad Clinical Spectrum of Epilepsies Associated With Protocadherin 19 Gene Mutation
por: Dell'Isola, Giovanni Battista, et al.
Publicado: (2022) -
Temporal Lobe Epilepsy and Psychiatric Comorbidity
por: Vinti, Valerio, et al.
Publicado: (2021) -
Sleep Disorders in Rett Syndrome and Rett-Related Disorders: A Narrative Review
por: Tascini, Giorgia, et al.
Publicado: (2022)